The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study.
 
Changhoon Yoo
Stock and Other Ownership Interests - Oncocross
Honoraria - Bayer; Ipsen; SERVIER
Consulting or Advisory Role - LSK BioPharma
Speakers' Bureau - Bayer; Celgene; Eisai; Ipsen; Merck Sharp & Dohme
Research Funding - AstraZeneca; Bayer; CKD pharm; SERVIER
 
Jwa Hoon Kim
No Relationships to Disclose
 
Min-Hee Ryu
Honoraria - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Sook Ryun Park
No Relationships to Disclose
 
Joycelyn Jie Xin Lee
Consulting or Advisory Role - Bayer; Ipsen
Research Funding - Bayer (Inst)
 
Wai Meng David Tai
Honoraria - Bayer
Consulting or Advisory Role - Bayer; Eisai; Ipsen
Research Funding - Bristol-Myers Squibb; Sirtex Medical
 
Stephen Lam Chan
Consulting or Advisory Role - AstraZeneca/MedImmune; MSD Oncology; Novartis
 
Baek-Yeol Ryoo
No Relationships to Disclose